USP30 and Ataxia: Moreover, a variety of DUBs-targeted agents have been tested for their ability to fight against non-cancer diseases, such as neurodegeneration, ataxia, Parkinson’s disease, Huntington’s disease, inflammatory diseases, and even SARS coronavirus infection Notably, MTX652, an USP30-targeted agent, has successfully completed its first Phase I clinical study, and has recently gained clearance from the US FDA to commence a Phase II trial as a potential candidate treatment for mitochondrial dysfunction To date, none USPs-targeted agents has yet been approved for clinical use.